Targeted Therapies in Ovarian Cancer
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Clinical Pearls:
- There have not been many targeted therapies developed in ovarian cancer
- Physicians still rely on a chemotherapy regimen to treat patients with ovarian cancer
- Although this regimen eliminates advanced disease about 80-90% of the time, the disease eventually comes back
- TargetingBRCAand PARP have proven to be good targets to develop further
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
